Our Life Sciences team offer legal advice specifically targeted to meet the needs of expanding and developing life sciences companies. Members of our team are instructed by a wide range of companies on matters covering all aspects of life sciences work. Particular strengths in this specialised area are commercial, corporate finance and M&A, dispute resolution / litigation, general advisory and regulatory (including pricing issues and the PPRS).


Demonstrating the depth of the practice, members of our team have acted for major national and multinational pharmaceutical companies, generic and later stage pharmaceutical companies and various biotechnology, medical diagnostics and medical devices companies.

Our team includes a number of lawyers ranked or mentioned in legal directories including Chambers UK and Legal 500.

Representative Matters

Commercial, including distribution and licensing

Negotiating and drafting, among other things:

  • transitional services agreements
  • licensing arrangements
  • development deals
  • research and development collaborations
  • manufacture and supply arrangements
  • distribution agreements
  • clinical trial agreements
  • royalty agreements
  • quality and pharmacovigilance agreements

Working with major accountancy practices on creating and developing cost-effective supply chains for cross-border pharmaceutical companies

Regulatory

  • Advising on the legal issues associated with global clinical trials, including the UK’s regulatory and legislative framework
  • Advising several UK pharmaceutical companies in their disputes with the UK Department of Health under the Pharmaceutical Price Regulation Schemes (PPRS)
  • Advising on the response to, and the implications of, an investigation by the MHRA
  • Advising on a response to, and the implications of, the EMA’s withdrawal of pharmaceutical from licence in the EU

Corporate finance and M&A

  • Advising on the acquisition and disposal of product portfolios and individual products from major pharmaceutical companies including Abbott, Novartis, Bayer and Hoffman La-Roche
  • Negotiating the financial arrangements (both syndicated facilities and high yield) behind major acquisitions of product portfolios and their refinancing
  • Acting on the £365 million disposal of Amdipharm to Cinven
  • Acting on the disposal of the parallel import and distribution business of Waymade Plc to Laxmico Ltd (t/a B&S Colorama)
  • Advising on the UK securities implications of Concordia Healthcare Corp’s US$1.2 billion acquisition of Covis Pharma
  • Advising on a rights issue and acquisition for a major product and research services provider to the pharmaceutical and chemical industries
  • Advising on raising equity finance for the marketing and manufacture in Europe of an unlicensed special
  • Advising on raising equity finance for the marketing and manufacture of a medical diagnostics product

Litigation and Dispute resolution

  • Acting in High Court proceedings concerning the transfer of an overseas import licence
  • Acting for a UK pharmaceutical company in connection with a dispute concerning a manufacturing and supply agreement
  • Advising a medical devices company in a dispute with its appointed CRO
  • Advising several UK pharmaceutical companies in their disputes with the UK Department of Health under the Pharmaceutical Price Regulation Schemes (PPRS)
  • Defending High Court proceedings brought against a US medical device manufacturer concerning allegations of breach of a distribution agreement
  • Advising a pharmaceutical company about defamatory reporting concerning one of its key products
  • Advising the manufacturer of a leading OTC product in its dispute with a UK supermarket chain
  • Acting as counsel to the expert in an expert determination concerning a long term collaborative arrangement between two life sciences companies

 

Upcoming Events :

Social Housing Annual Conference 2017

Thu 09 Nov 2017

200 Aldersgate, London, EC1A 4HD

Read more

Recognised by Chambers UK as a 'Leader in their field' within 'Corporate/M&A: Mid-Market', Catherine handles all aspects of corporate finance, she focuses on transactions in the media and life science sectors and is "approachable, personable and knowledgeable."

Chambers and Partners UK, 2016